Gamze Kuser-Abali

Gamze Kuser-Abali

Auto-generated profile, based on publicly available information

Gamze Kuser-Abali

Department of Cancer Medicine, Monash University, Melbourne, VIC 3004, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
GKGamze Kuser-Abali
Gamze Kuser-Abali
AAAhmet Alptekin
Ahmet Alptekin
MLMichael Lewis
Michael Lewis
IGIsla P. Garraway
Isla P. Garraway
BCBekir Cinar
Bekir Cinar
The transcriptional co-activator Yes-associated protein 1 (YAP1), a key nuclear effector of the Hippo pathway, is a potent oncogene, and yet, the interaction between YAP1 and androgen receptor (AR) remains unexplored. Here we identify YAP1 as a physiological binding partner and positive regulator of AR in prostate cancer. YAP1 and AR co-localize and interact with each other predominantly within cell nuclei by an androgen-dependent mechanism in a hormone naive and an androgen-independent mechanism in castration-resistant prostate cancer cells. The growth suppressor MST1 kinase modulates androgen-dependent and -independent nuclear YAP1–AR interactions through directly regulating YAP1 nuclear accumulation. Disruption of YAP1 signalling by genetic (RNAi) and pharmacological (Verteporfin) approaches suppresses AR-dependent gene expression and prostate cancer cell growth. These findings indicate that the YAP1–AR axis may have a critical role in prostate cancer progression and serves as a viable drug target.

3 February 2014 in Epigenetics
Verified
Journal Article
Closed access
GKGamze Kuser-Abali
Gamze Kuser-Abali
AAAhmet Alptekin
Ahmet Alptekin
BCBekir Cinar
Bekir Cinar
Hippo-like MST1 protein kinase regulates cell growth, organ size, and carcinogenesis. Reduction or loss of MST1 expression is implicated in poor cancer prognosis. However, the mechanism leading to MST1 silencing remains elusive. Here, we report that both MYC and EZH2 function as potent suppressors of MST1 expression in human prostate cancer cells. We demonstrated that concurrent overexpression of MYC and EZH2 correlated with the reduction or loss of MST1 expression, as shown by RT-qPCR and immunoblotting. Methylation sensitive PCR and bisulfite genomic DNA sequencing showed that DNA methylation caused MST1 silencing. Pharmacologic and RNAi experiments revealed that MYC and EZH2 silenced MST1 expression by inhibiting its promoter activity, and that EZH2 was a mediator of the MYC-induced silencing of MST1. In addition, MYC contributed to MST1 silencing by partly inhibiting the expression of microRNA-26a/b, a negative regulator of EZH2. As shown by ChIP assays, EZH2-induced DNA methylation and H3K27me3 modification, which was accompanied by a reduced H3K4me3 mark and RNA polymerase II occupancy on the MST1 promoter CpG region, were the underlying cause of MST1 silencing. Moreover, potent pharmacologic inhibitors of MYC or EZH2 suppressed prostate cancer cell growth in vitro, and the knockdown of MST1 caused cells' resistance to MYC and EZH2 inhibitor-induced growth retardation. These findings indicate that MYC, in concert with EZH2, epigenetically attenuates MST1 expression and suggest that the loss of MST1/Hippo functions is critical for the MYC or EZH2 mediation of cancer cell survival.

14 March 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GKGamze Kuser-Abali
Gamze Kuser-Abali
LGLu Gong
Lu Gong
JYJiawei Yan
Jiawei Yan
QLQingqing Liu
Qingqing Liu
WZWeiqi Zeng
Weiqi Zeng
ZYZhi-Min Yuan
Zhi-Min Yuan
Significance: p53 is widely perceived as a determinant of sensitivity to radio-/chemotherapy. We report a distinct mechanism whereby p53-regulated MDM2 works together with MDMX to modulate sensitivity to DNA damage by controlling EZH2 (enhancer of zeste homolog 2) turnover. Our work uncovers a mechanism of chromatin modification underlying tissue sensitivity to DNA damage. The MDM2/MDMX disruptor can be used for protecting renewable tissues from chemo-/radiotherapy-induced damage, and the EZH2 inhibitor for sensitizing p53-mutant cancer cells to chemo-/radiotherapy.

1 May 2020 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
LGLu Gong
Lu Gong
XPXiao Pan
Xiao Pan
GAGamze K. Abali
Gamze K. Abali
JLJohn B. Little
John B. Little
ZYZhi-Min Yuan
Zhi-Min Yuan

1 May 2013 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
GKGamze Küser-Abali
Gamze Küser-Abali
FÖFerruh Özcan
Ferruh Özcan
AUAsli Ugurlu
Asli Ugurlu
AUAvni Uysal
Avni Uysal
SFStefan H. Fuss
Stefan H. Fuss
KBKuyas Bugra-Bilge
Kuyas Bugra-Bilge
Purpose. To investigate the role of the serine/threonine kinase SIK2, a member of the salt-inducible kinase (SIK) family, in insulin-dependent cell survival and hyperglycemia-induced cell death in Müller glia. Methods. Expression studies were performed by RT-PCR, immunostaining, Northern blotting, and immunoblotting. Insulin-dependent changes in SIK2 activity were investigated by in vitro kinase assays in MIO-M1 Müller cell line. Akt activation was studied by immunoblotting and cell death by TUNEL assay. The potential role of SIK2 in insulin signaling was explored by overexpression and sh-RNA knock-down approaches. Effects of hyperglycemia were studied in vitro and in vivo in streptozotocin-injected rats. Results. SIK2 expression was detected throughout adult retina, except for the outer nuclear layer. Insulin stimulation of MIO-M1 cells resulted in a rapid 2-fold increase of SIK2 activity, increased insulin receptor substrate 1 (IRS1)-SIK2 interaction, and reduced cell death. pAkt levels following insulin treatment were modulated by SIK2 activity. Under hyperglycemia, increased SIK2 activity/expression was concomitant to decreased Akt activation and enhanced apoptosis; whereas knockdown of SIK2 under normo- and hyperglycemic conditions resulted in a rapid increase in pAkt levels and blunted cell death. SIK2 overexpression under normoglycemia had an opposite effect. SIK2 activity increased significantly within 2 weeks of induction of hyperglycemia in the rat retina. Conclusions. Results indicate that SIK2 functions as a negative modulator of the insulin-dependent survival pathway and contributes to hyperglycemia-induced cell death of Müller glia in vitro. Although still hypothetical at this point, our study suggests that SIK2 could serve a similar role during the development of diabetic retinopathy in vivo and that it represents a potential target to control disease progression.

25 April 2018 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
MMMary Ellen Molloy
Mary Ellen Molloy
MLMonika Lewinska
Monika Lewinska
AWAmanda K Williamson
Amanda K Williamson
TNThanh Thao Nguyen
Thanh Thao Nguyen
GKGamze Kuser-Abali
Gamze Kuser-Abali
ZYZhi-Min Yuan
Zhi-Min Yuan
ZBTB7A, a member of the POZ/BTB and Krüppel (POK) family of transcription factors, has been shown to have a context-dependent role in cancer development and progression. The role of ZBTB7A in estrogen receptor alpha (ERα)-positive breast cancer is largely unknown. Approximately 70% of breast cancers are classified as ERα-positive. ERα carries out the biological effects of estrogen and its expression level dictates response to endocrine therapies and prognosis for breast cancer patients. In this study, we find that ZBTB7A transcriptionally regulates ERα expression in ERα-positive breast cancer cell lines by binding to the ESR1 promoter leading to increased transcription of ERα. Inhibition of ZBTB7A in ERα-positive cells results in decreased estrogen responsiveness as demonstrated by diminished estrogen-response element-driven luciferase reporter activity, induction of estrogen target genes, and estrogen-stimulated growth. We also report that ERα potentiates ZBTB7A expression via a post-translational mechanism, suggesting the presence of a positive feedback loop between ZBTB7A and ERα, conferring sensitivity to estrogen in breast cancer. Clinically, we find that ZBTB7A and ERα are often co-expressed in breast cancers and that high ZBTB7A expression correlates with improved overall and relapse-free survival for breast cancer patients. Importantly, high ZBTB7A expression predicts a more favorable outcome for patients treated with endocrine therapies. Together, these findings demonstrate that ZBTB7A contributes to the transcriptional program maintaining ERα expression and potentially an endocrine therapy-responsive phenotype in breast cancer.